Figures & data
Table I. Biologic therapies in SLE — summary of trials.
Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, . Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000;43:1790–800. Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, . Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford). 2009;48:1451–4. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, . Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1785–96. McBride JM, Wallace D, Yao Z, Morimoto A, Jiang J, Maciuca R, . Dose-dependent modulation of Interferon regulated genes with in administration of single and repeat doses of rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE (abstract 2072). Arthritis Rheum. 2009;60(Suppl):S775–6. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, . Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542–52. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, . Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–33. Furie RA, Looney RJ, Rovin B, Latinis KM, Appel G, Sanchez-Guerrero J, . Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized double-blind phase III LUNAR study. Arthritis Rheum. 2009;60(Suppl 1):S429. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8:R74. Wallace D, Kalunian K, Petri M, Strand V, Killgallen B, Barry A, . Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIB study. Ann Rheum Dis. 2010;69(Suppl3):558. Navarra S, Ilianova E, Bae S, Guzman R, Tanasescu C, Gallacher A, . Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann Rheum Dis. 2010;69(Suppl3):555. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, . Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56:4142–50. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008;58:2470–80. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:3251–8. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, . A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48:719–27. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, . The efficacy and safety of abatacept in patients with non-life-threatening manifestations of SLE: Results of A 12-month exploratory study. Arthritis Rheum. 2010;62:3077–87.